BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCardia (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, announced its CEO Peter Altman's participation in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2025. The presentation, scheduled for 3:40 p.m. EDT, will focus on recent business developments and the company's therapeutic pipeline, particularly highlighting their lead product CardiAMP, an autologous cell therapy for treating ischemic heart failure. The session will be moderated by Jim Molloy, AGP's Managing Director of Equity Research Biotechnology & Specialty Pharmaceuticals.
Details
News Market Reaction – BCDA
The recorded move for BCDA in the trading session of this news was -4.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025.
Dr. Altman will share recent business developments on the Company’s therapeutic development pipeline with a focus on its lead CardiAMP autologous cell therapy for the treatment of ischemic heart failure.
Fireside Chat Details:
Date: Wednesday, May 21, 2025
Time: 03:40 p.m. EDT
Speaker: Peter Altman Ph.D., CEO
Moderator: Jim Molloy, AGP Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals
Webcast: https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.
MEDIA CONTACT: Miranda Peto, Investor Relations mpeto@biocardia.com (650) 226-0120 INVESTOR CONTACT: David McClung, Chief Financial Officer investors@biocardia.com (650) 226-0120
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.